ALK Canada

For more than 100 years, ALK has been at the forefront of allergy research and treatment. We’re on a mission to help even more people globally, reaching 5 million people a year by 2030. ALK manufactures and commercializes a wide range of allergen extracts used in allergy skin testing, sublingual immunotherapy tablets, and subcutaneous immunotherapy (allergy shots). In addition to its core business in environmental allergies, ALK is conducting clinical research in Canada to bring innovative therapeutics for the treatment of food allergies and has also acquired exclusive rights to commercialize the first nasal epinephrine, which is currently under review by Health Canada. ALK Canada currently employs ~30 colleagues and plans to rapidly expand over the next 3 years to meet the demand of allergy patients and physicians across the country.